73 results about "Corticosterone" patented technology

The invention discloses a clinical-grade serum-free medium for adherent culture of human neural stem cells. The medium disclosed by the invention comprises a basic medium, basic nutrition additives, plant-based human serum albumins, saccharides, lipid, hormones, antioxidants and related substances for promoting metabolism; the basic medium is prepared from commercial DMEM / F12 and a commercial neurobasal medium according to a ratio of 1:1; the basic nutrition additives comprise insulin, holo-transferrin, apo-transferrin, putrescine, progesterone and sodium selenite; the hormones comprise biotin, corticosterone, lipoic acid, Ve and Ve acetic ester; the antioxidants comprise human-derived catalase, human-derived superoxide dismutase, glutathione and Vc; the related substances for promoting metabolism comprise carnitine, T3 and ethanol amine. The medium can improve a cell expansion speed by two to three times, well keeps stem properties of the neural stem cells, keeps the cell differentiation potential of the neural stem cells and eliminates potential animal-origin endotoxin and viral pollution.

An immunoassay apparatus on a chip is disclosed, which can quantitatively measure the concentration of hormones (particularly corticosterone and progesterone) in a biological sample. Such an apparatus can be designed to be used in the field, saving time and money for those taking the measurements. The measurements are made within a micro-fluidic channel configured on a substrate of a chip, which is loaded using simple capillary forces. Competitive immunoassay can be performed, with the competing agents being the hormone (e.g., antigen) and hormone-coated latex beads (e.g., both pre-mixed in a methanol solution).

The invention discloses an improved Neurobasal B27 culture medium. One liter of a Neurobasal culture solution comprises 0.09-0.11 g of biotin, 18-22 micrograms of corticosterone, 1-3 g of L-carnitine, 0.9-1.1 g of linoleic acid, 0.9-1.1 g of ethanol amine, 0.9-1.1 g of linolenic acid, 13-17 g of D(+)-galactose, 6-7 micrograms of progesterone, 15-17 g of putrescine dihydrochloride, 0.08-0.12 g of retinyl acetate, 2.2-2.8 g of thyroid-hormone-removing bovine serum albumin, 0.8-1.5 g of DL-alpha-tocopherol, 2-3 g of catalase, 0.9-1.2 g of DL-alpha-tocopheryl acetate, 0.8-1.3 g of reduced glutathione, 42-52 micrograms of lipoic acid, 2-3 g of superoxide dismutase, 4-6 g of transferring, 3-5 g of human insulin and 0.12-0.16 mg of sodium selenite. The invention further discloses a preparing method and application of the improved Neurobasal B27 culture medium. The improved Neurobasal B27 culture medium can be used for researching the influence of thyroid hormones on the process that embryonic stem cells are differentiated into nerve cells.

The invention provides a qualitative and quantitative detection method of steroid hormones in saliva and particularly relates to a liquid chromatography tandem mass spectrometry detection method of eight steroid hormones in saliva; the steroid hormones include 17-hydroxyprogesterone, progesterone, androstenedione, testosterone, dehydroepiandrosterone, cortisol, corticosterone and aldosterone. Thedetection method herein includes: freezing a human saliva sample, allowing protein precipitation, ultrasonically extracting, filtering, mixing the filtrate with an internal standard liquid, carrying out reversed-phase SPE (solid phase extraction) column purification, and chemically deriving the target products. Full dissolution of the target hormones in saliva is guaranteed; disturbance of impurities in the saliva is eliminated; accuracy and stability are ensured for detection results. The eight hormones are synchronously, qualitatively and quantitatively analyzed by liquid chromatographic separation and mass spectrometric ion-pairing detection. The detection method herein is suitable for synchronous batch detection of hormone molecules having similar structure and approximate chemi-physical properties, has the advantages of high sensitivity, high precision, good repeatability, high detection speed and the like, fully meets the needs of clinical detection, and has high clinical application value.

The invention belongs to the field of medicines and relates to a dihydro isoquinoline compound and application thereof in treatment of mental disorder, related to emotion, especially depressive disorder. Shown in a structural formula I, the dihydro isoquinoline compound has good protection activity on PC12 cells damaged under the induction action of corticosterone in an in vitro experiment, which suggests that the dihydro isoquinoline compound has a function of protecting nerve cells, further experiments verify that the dihydro isoquinoline compound can effectively improve level of BNDF (brain-derived neurotrophic factor) in nerve cells, the oxidation resistance of the nerve cells can also be effectively enhanced, and growth of the nerve cells is promoted; the dihydro isoquinoline compound has potential of treating mental disorder owning to repairing and protective effect on the nerve cells, is preferable for treating emotion and cognitive mental disorders, such as depressive disorder, senile dementia, anxiety, obsession and schizophrenia and is especially preferable for treatment of depression. In vivo experiments, including forced swimming and open field experiment, the dihydro isoquinoline compound shows obvious effect of alleviating depressive state of experimental animals respectively. The formula (I) is described in the specification.

Compositions including combinations of β-glucan and Withania somnifera for increasing the immune activity of certain target cytokines and phagocytosis, and reducing cortisol or corticosterone. Methods of improving immunity activity under periods of stress including chronic stress with a combination of β-glucan and Withania somnifera are also described. Particular combinations of β-glucan and Withania somnifera synergistically increases the immune activity of the cytokines IL-12 and IL-6 over expected values.

The invention belongs to the field of medicines and relates to a dihydro isoquinoline compound and application thereof in treatment of mental disorder, related to emotion, especially depressive disorder. Shown in a structural formula I, the dihydro isoquinoline compound has good protection activity on PC12 cells damaged under the induction action of corticosterone in an in vitro experiment, which suggests that the dihydro isoquinoline compound has a function of protecting nerve cells, further experiments verify that the dihydro isoquinoline compound can effectively improve level of BNDF (brain-derived neurotrophic factor) in nerve cells, the oxidation resistance of the nerve cells can also be effectively enhanced, and growth of the nerve cells is promoted; the dihydro isoquinoline compound has potential of treating mental disorder owning to repairing and protective effect on the nerve cells, is preferable for treating emotion and cognitive mental disorders, such as depressive disorder, senile dementia, anxiety, obsession and schizophrenia and is especially preferable for treatment of depression. In vivo experiments, including forced swimming and open field experiment, the dihydro isoquinoline compound shows obvious effect of alleviating depressive state of experimental animals respectively. The formula (I) is described in the specification.

The invention belongs to the field of analytical chemistry and clinical medicine and relates to a plasma metabolization micromolecule marker related to the human non-small-cell lung cancer and an application of the plasma metabolization micromolecule marker. The plasma metabolization micromolecule marker related to the human non-small-cell lung cancer is one or more of cortisol, corticosterone and 4-methoxyphenylacetic acid. The plasma metabolization micromolecule marker is prepared from cortisol, corticosterone and 4-methoxyphenylacetic acid. The content range (95% confidence interval) of cortisol is 0.00018-0.00067, the content range (95% confidence interval) of corticosterone is 0.000029-0.00010, the content range (95% confidence interval) of 4-methoxyphenylacetic acid is 0.000015-0.000022, and metabolite can prompt occurrence of tumors within the ranges. The horizontal range, corresponding to a normal group, of cortisol is 0.0030-0.0037, the horizontal range, corresponding to the normal group, of corticosterone is 0.00044-0.00056, and the horizontal range, corresponding to the normal group, of 4-methoxyphenylacetic acid is 7.39 E-07-2.09 E-06. The plasma metabolization micromolecule marker is a novel biomarker, compared with a traditional protein biomarker, the relevance between the marker and the disease outcome is higher, and the plasma metabolization micromolecule marker is stable, minimally invasive, easy to detect and accurate in quantitation.

An expression cassette, operable in a recombinant host, comprising a heterologous DNA coding sequence encoding a protein, which is functional, alone or in cooperation with one or more additional proteins of catalyzing an oxidation step in the biological pathway, for conversion of cholesterol into hydrocortisone, which step is selected from the group consisting of:< / PTEXT>the conversion of cholesterol to pregnenolone;< / PTEXT>the conversion of pregnenolone to progesterone;< / PTEXT>the conversion of progesterone to 17alpha-hydroxyprogesterone;< / PTEXT>the conversion of 17alpha-hydroxyprogesterone to cortexolone;< / PTEXT>the conversion of cortexolone to hydrocortisone, and the corresponding control sequences effective in that host.< / PTEXT>

The present invention provides cortexolone 17α-propionate for use in the treatment of skin wounds and / or atrophic skin disorders. The present invention also provides pharmaceutical or cosmetic compositions comprising cortexolone 17α-propionate for use in the treatment of skin wounds and / or of atrophic skin disorders.

The invention relates to a nerve cell serum-free medium and application thereof. The nerve cell serum-free medium comprises the following components: a basic medium D-MEM (Dulbecco's Modified Eagle Medium); growth factors, namely a basic fibroblast growth factor of which the final concentration is 0.1-10mu g / ml, an epidermal growth factor of which the final concentration is 0.1-10mu g / ml, a vascular endothelial growth factor of which the final concentration is 0.1-10mu g / ml, and a brain-derived neurotrophic factor of which the final concentration is 0.01-1mu g / ml; proteins, namely a cattle serum protein of which the final concentration is 0.001-0.1mu g / ml, and transferrin of which the final concentration is 10-500mu g / ml; hormones, namely insulin of which the final concentration is 1-100mu g / ml, an insulin like growth hormone 1 of which the final concentration is 0.1-10mu g / ml, corticosterone of which the final concentration is 1-100mu g / ml, and progesterone of which the final concentration is 0.1-10mu g / ml; and other substances, namely a soybean trypsin inhibitor of which the final concentration is 0.1-20mu g / ml, butanediamine of which the final concentration is 1-100mu g / ml, and sodium selenite of which the final concentration is 1-1000mu g / ml. Compared with the prior art, the invention provides an efficient and reliable serum-free medium for rat nerve cell culture.

The invention discloses a method for determination of calcium concentration in a rat spinal dorsal horn neuron. The method includes: taking a SD neonatal rat, conducting disinfection and then executing it, separating the spinal dorsal horn tissue, stripping a spinal cord outer membrane, cutting the tissue into small pieces, transferring the pieces into a centrifuge tube, and adding trypsin to conduct digestion; then adding a DMEM / F12 medium containing 10% fetal calf serum to terminate the digestion; conducting blowing to obtain a cell suspension, performing centrifugation and discarding the supernatant; adding an NB / B27 medium to resuspend cells, inoculating the cells into a special laser confocal dish, and performing standing in an incubation box; adding an NB / B27 medium containing penicillin and streptomycin; performing loading with a fluorescent indicator, putting the cells into the incubation box to perform incubation, rinsing the NB medium, then covering the cells with the NB medium, and carrying out scanning detection with a laser scanning confocal microscope. The method for determination of calcium concentration in the rat spinal dorsal horn neuron provided by the invention can be used for observing the influence of corticosterone on the Ca<2+> concentration of the cultured spinal dorsal horn neuron, and creates conditions for studying the regulation of corticosterone on spinal dorsal horn sensory neuron functions and the action mechanism thereof.

The invention discloses hyponicosidesA-D(1-4) separated from Hypericum japonicum, a pharmaceutical composition taking the hyponicosidesA-D(1-4) as an effective component and application of the hyponicosidesA-D(1-4) to preparation of drugs for treating mental diseases. The hyponicosidesA-D(1-4) disclosed by the invention have remarkable protection effects on PC12 cells damaged by induction of corticosterone, so that the hyponicosidesA-D(1-4) have potential for treating mental diseases, preferably treating mental diseases such as depression, senile dementia, anxiety, obsessive-compulsive disorder and schizophrenia of emotional and cognitive impairment.